Haisco Pharmaceutical Group (002653.SZ): The IND application for the innovative drug HSK41959 has been accepted.

Haisco Pharmaceutical Group (002653.SZ) announced that the company has received the acceptance letter for the Investigational New Drug (IND) application of the innovative drug HSK41959 tablets. HSK41959 tablets are orally administered, potent, and highly selective small molecule inhibitors developed by the company, intended for the treatment of advanced solid tumors. According to the announcement of the National Medical Products Administration on the Classification of Chemical Drug Registration and Data Requirements for Declaration (No. 44 of 2020), this product belongs to Class 1 of chemical drugs. Preclinical research results have shown that HSK41959 significantly inhibits tumor cell proliferation activity, demonstrating excellent anti-tumor efficacy, as well as good tolerability and a wide safety margin. It is a promising small molecule anti-tumor drug with great development potential, offering a new treatment option for patients with advanced solid tumors.